News from vm biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 03, 2017, 07:00 ET VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers

VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea (KOSDAQ: 084990), today announced the first patient was dosed in the...


Feb 09, 2017, 08:01 ET VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)

VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, South Korea (KOSDAQ: 084990), today announced that the scientific journal,...


Aug 02, 2016, 09:00 ET VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease

VM BioPharma, the US division of ViroMed Co., Ltd. in Seoul, South Korea (KOSDAQ: 084990), announced today that the company has obtained...


Jun 27, 2016, 08:00 ET VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea (KOSDAQ:084990), today announced the first patient was dosed in the...


May 17, 2016, 11:00 ET VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis (ALS)

VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, South Korea (KOSDAQ:084990), today announced that the U.S. Food and Drug...